冠心病合并急性心力衰竭患者应用新活素的临床价值

The clinical value of Xinhuosu in patients with coronary heart disease and acute heart failure

目的 分析冻干重组人脑利钠肽(商品名:新活素)在冠心病合并急性心力衰竭中的临床应用价值。方法 60例冠心病合并急性心力衰竭患者,根据随机数字表法分为对照组与研究组,每组30例。对照组接受硝酸异山梨酯治疗,研究组接受硝酸异山梨酯与新活素联合治疗。对比两组临床治疗效果以及治疗前后各项生命体征[舒张压、收缩压、心率、氨基末端脑钠肽前体(NT-proBNP)]。结果 与对照组(80.00%)相比,研究组治疗总有效率(96.67%)显著较高,组间比较存在统计学差异(χ2=4.043,P<0.05)。治疗后,两组舒张压、收缩压、心率、NT-proBNP水平显著低于治疗前,且研究组舒张压(83.11±2.13)mm Hg(1 mm Hg=0.133 kPa)、收缩压(108.37±4.62)mm Hg、心率(82.16±1.74)次/min、NT-proBNP(1251.39±46.23)pg/ml显著低于对照组的(87.16±2.72)mm Hg、(123.28±4.19)mm Hg、(87.16±2.16)次/min、(1763.27±95.16)pg/ml,存在统计学差异(P<0.05)。结论 将新活素应用到冠心病合并急性心力衰竭治疗中,能有效调节患者的心功能,促使患者病情转归,利于提高整体疗效,具有较高的临床应用价值,值得推广。

Objective To analyze the clinical value of lyophilized recombinant human brain natriuretic peptide(trade name:Xinhuosu)in patients with coronary heart disease and acute heart failure.Methods 60 patients with coronary heart disease and acute heart failure were divided into a control group and a study group according to the random numerical table,with 30 cases in each group.The control group was treated with isosorbide dinitrate,and the study group was treated with isosorbide dinitrate and Xinhuosu.The clinical therapeutic effect and the vital signs[diastolic blood pressure,systolic blood pressure,heart rate,N-terminal pro-brain natriuretic peptide(NT-proBNP)]before and after treatment were compared between the two groups.Results Compared with the control group(80.00%),the total effective rate of the study group(96.67%)was significantly higher,and the difference between groups was statistically significant(χ2=4.043,P<0.05).After treatment,the diastolic blood pressure,systolic blood pressure,heart rate and NT-proBNP levels in both groups were significantly lower than those before treatment;the study group had diastolic blood pressure of(83.11±2.13)mm Hg(1 mm Hg=0.133 kPa),systolic blood pressure of(108.37±4.62)mm Hg,heart rate of(82.16±1.74)beats/min,and NT-proBNP of(1251.39±46.23)pg/ml,which were significantly lower than(87.16±2.72)mm Hg,(123.28±4.19)mm Hg,(87.16±2.16)beats/min,and(1763.27±95.16)pg/ml in the control group;the difference between groups was statistically significant(P<0.05).Conclusion The application of Xinhuosu in the treatment of coronary heart disease combined with acute heart failure can effectively regulate the patient's heart function,promote the prognosis of patients,and improve the overall efficacy.It has high clinical application value,and is worth promoting.